Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 5/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.45 |
| ▸ | KDR | P35968 | 6/20 | 0.45 |
| ▸ | MET | P08581 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17486951 | 0.95 | FGFR2 (0.48) | PDGFRAPDGFRBFGFR2KDRMET | |
| SCHEMBL12663519 | 0.89 | PDGFRA (0.51) | PDGFRAPDGFRBFGFR2KDR | |
| SCHEMBL16062321 | 0.85 | PDGFRA (0.59) | PDGFRAPDGFRBFGFR2KDRMET | |
| SCHEMBL4141203 | 0.83 | FGFR2 (0.60) | PDGFRAPDGFRBFGFR2KDR | |
| SCHEMBL13980801 | 0.81 | PDGFRA (0.60) | PDGFRAPDGFRBFGFR2KDR | |
| SCHEMBL14540924 | 0.81 | FGFR2 (0.54) | PDGFRAPDGFRBFGFR2KDR | |
| SCHEMBL12663357 | 0.81 | PDGFRA (0.44) | PDGFRAPDGFRBFGFR2KDRMET | |
| SCHEMBL14540484 | 0.81 | MET (0.44) | PDGFRAPDGFRBFGFR2KDRMET | |
| SCHEMBL14609453 | 0.81 | PDGFRA (0.47) | PDGFRAPDGFRBFGFR2KDRMET | |
| SCHEMBL12663554 | 0.79 | AXL (0.60) | PDGFRAPDGFRBFGFR2KDRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20160031818-A1 | Metabolites of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | MET, ABL1, KRAS | PDGFRA 25/4885PDGFRB 44/4885FGFR2 464/4885 |
| US-20160031818-A1 | Metabolites of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | IDH1, NTRK3, FGFR4 | PDGFRA 14/4885PDGFRB 29/4885FGFR2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.